Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.

Block GA, Pergola PE, Fishbane S, Martins JG, LeWinter RD, Uhlig K, Neylan JF, Chertow GM.

Nephrol Dial Transplant. 2018 Oct 30. doi: 10.1093/ndt/gfy318. [Epub ahead of print]

PMID:
30380116
2.

Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.

McCullough PA, Uhlig K, Neylan JF, Pergola PE, Fishbane S.

Am J Cardiol. 2018 Aug 15;122(4):683-688. doi: 10.1016/j.amjcard.2018.04.062. Epub 2018 May 19.

3.

Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia.

Pergola PE, Fishbane S, LeWinter RD, Neylan JF, Uhlig K, Block GA, Chertow GM.

Am J Hematol. 2018 Jun;93(6):E154-E156. doi: 10.1002/ajh.25088. Epub 2018 Mar 30. No abstract available.

4.

Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease.

Chertow GM, Block GA, Neylan JF, Pergola PE, Uhlig K, Fishbane S.

PLoS One. 2017 Nov 29;12(11):e0188712. doi: 10.1371/journal.pone.0188712. eCollection 2017.

5.

Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.

Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES; Sirolimus CONVERT Trial Study Group.

Transplantation. 2011 Aug 15;92(3):303-10. doi: 10.1097/TP.0b013e3182247ae2.

PMID:
21792049
6.

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.

Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group.

Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41.

PMID:
19155978
7.

Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.

Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF; Sirolimus High-Risk Study Group.

Transplantation. 2008 Nov 15;86(9):1187-95. doi: 10.1097/TP.0b013e318187bab0.

PMID:
19005398
8.

Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression.

Burke JT, Brault Y, Kahan BD, Hricik DE, Grinyó JM, Chapman JR, Polinsky M, Neylan JF.

Transpl Int. 2008 May;21(5):434-40. doi: 10.1111/j.1432-2277.2007.00624.x. Epub 2008 Jan 9.

9.

Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.

Legendre C, Brault Y, Morales JM, Oberbauer R, Altieri P, Riad H, Mahony J, Messina M, Pussell B, Martínez JG, Lelong M, Burke JT, Neylan JF; Rapamune Maintenance Regimen Study Group.

Clin Transplant. 2007 May-Jun;21(3):330-6.

PMID:
17488381
10.

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.

Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF.

J Am Soc Nephrol. 2006 Feb;17(2):581-9.

11.

Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.

Russ G, Segoloni G, Oberbauer R, Legendre C, Mota A, Eris J, Grinyó JM, Friend P, Lawen J, Hartmann A, Schena FP, Lelong M, Burke JT, Neylan JF; Rapamune Maintenance Regimen Study Group.

Transplantation. 2005 Nov 15;80(9):1204-11.

PMID:
16314787
12.

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.

Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF; Rapamune Maintenance Regimen Study Group.

Transpl Int. 2005 Jan;18(1):22-8. Erratum in: Transpl Int. 2005 Mar;18(3):369.

13.

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years.

Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, Claesson K, Castagneto M, Campistol JM, Hutchison B, Burke JT, Yilmaz S, Häyry P, Neylan JF; Rapamune Maintenance Regimen Trial.

Am J Transplant. 2004 Jun;4(6):953-61.

14.

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, Burke JT, Brault Y, Gioud-Paquet M, Scarola JA, Neylan JF; Rapamune Maintenance Regimen Trial.

J Am Soc Nephrol. 2004 Mar;15(3):809-17.

15.

The influence of Duffy blood group on renal allograft outcome in African Americans.

Akalin E, Neylan JF.

Transplantation. 2003 May 15;75(9):1496-500.

PMID:
12792503
16.

Tacrolimus, cyclosporine and plasma lipoproteins in renal transplant recipients.

Venkiteswaran K, Sgoutas DS, Santanam N, Neylan JF.

Transpl Int. 2001 Dec;14(6):405-10.

PMID:
11793038
17.

Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology.

Akalin E, Hendrix RC, Polavarapu RG, Pearson TC, Neylan JF, Larsen CP, Lakkis FG.

Transplantation. 2001 Sep 15;72(5):948-53.

PMID:
11571464
18.

Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.

Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.

Transpl Infect Dis. 2000 Sep;2(3):112-7.

PMID:
11429021
19.

Payment for immunosuppression after organ transplantation. American Society of Transplantation.

Kasiske BL, Cohen D, Lucey MR, Neylan JF.

JAMA. 2000 May 10;283(18):2445-50.

PMID:
10815094
20.

The allocation of cadaver kidneys for transplantation in the United States: consensus and controversy. ASN Transplant Advisory Group. American Society of Nephrology.

Neylan JF, Sayegh MH, Coffman TM, Danovitch GM, Krensky AM, Strom TB, Turka LA, Harmon WE.

J Am Soc Nephrol. 1999 Oct;10(10):2237-43. Review. No abstract available.

21.

The role of tacrolimus in adult kidney transplantation: a review.

Laskow DA, Neylan JF 3rd, Shapiro RS, Pirsch JD, Vergne-Marini PJ, Tomlanovich SJ.

Clin Transplant. 1998 Dec;12(6):489-503. Review.

PMID:
9850440
22.

Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine.

Neylan JF, Sullivan EM, Steinwald B, Goss TF.

Am J Kidney Dis. 1998 Nov;32(5):770-7.

PMID:
9820446
23.

Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.

Gaber AO, First MR, Tesi RJ, Gaston RS, Mendez R, Mulloy LL, Light JA, Gaber LW, Squiers E, Taylor RJ, Neylan JF, Steiner RW, Knechtle S, Norman DJ, Shihab F, Basadonna G, Brennan DC, Hodge EE, Kahan BD, Kahan L, Steinberg S, Woodle ES, Chan L, Ham JM, Schroeder TJ, et al.

Transplantation. 1998 Jul 15;66(1):29-37.

PMID:
9679818
27.

Drainage of the exocrine pancreas in clinical transplantation: comparison of bladder versus enteric drainage in a consecutive series.

Pearson TC, Santamaria PJ, Routenberg KL, O'Brien DP, Whelchel JD, Neylan JF, Larsen CP.

Clin Transplant. 1997 Jun;11(3):201-5.

PMID:
9193842
28.

Microchimerism and rejection in clinical transplantation.

Elwood ET, Larsen CP, Maurer DH, Routenberg KL, Neylan JF, Whelchel JD, O'Brien DP, Pearson TC.

Lancet. 1997 May 10;349(9062):1358-60.

PMID:
9149698
29.

The Ad Hoc Committee report on estimating the future workforce and training requirements for nephrology. The Ad Hoc Committee on Nephrology Manpower Needs.

Neilson EG, Hull AR, Wish JB, Neylan JF, Sherman D, Suki WN.

J Am Soc Nephrol. 1997 May;8(5 Suppl 9):S1-4. No abstract available.

30.
31.

One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group.

Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ.

Transplantation. 1996 Jun 15;61(11):1576-81.

PMID:
8669100
32.

Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.

Vincenti F, Danovitch GM, Neylan JF, Steiner RW, Everson MP, Gaston RS.

Transplantation. 1996 Feb 27;61(4):573-7.

PMID:
8610383
33.

Evolving strategies in immunosuppressive therapy: the Emory experience.

Whelchel JD, Hymes LC, Hochgelerent EL, Larsen CP, Lowance DC, O'Brien DP, Neylan JF, Pearson TC, Warshaw BL.

Clin Transpl. 1996:249-55.

PMID:
9286574
34.

Delayed urinary bladder leak after combined kidney-pancreas transplantation. Association with penile prosthesis implantation.

Pearson TC, Futral AA, Routenberg KL, O'Brien DP, Whelchel JD, Neylan JF, Larsen CP.

Transplantation. 1995 Sep 27;60(6):624-6. No abstract available.

PMID:
7570965
35.

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial.

Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, Snydman DR, Freeman R, Lorber MI, Rubin RH.

Ann Intern Med. 1995 Jul 1;123(1):18-26.

PMID:
7762909
37.

Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients.

Apanay DC, Neylan JF, Ragab MS, Sgoutas DS.

Transplantation. 1994 Sep 27;58(6):663-9.

PMID:
7524202
38.
39.

The evaluation of candidates for renal transplantation. The current practice of U.S. transplant centers.

Ramos EL, Kasiske BL, Alexander SR, Danovitch GM, Harmon WE, Kahana L, Kiresuk TJ, Neylan JF.

Transplantation. 1994 Feb 27;57(4):490-7.

PMID:
7509515
40.

Hypertension after renal transplantation.

First MR, Neylan JF, Rocher LL, Tejani A.

J Am Soc Nephrol. 1994 Feb;4(8 Suppl):S30-6. Review.

41.

Racial issues in renal transplantation: the Emory University experience.

Whelchel JD, Neylan JF, Frederickson ED, Hochgelerent EL, Hymes LC, Larsen CP, Lowance DC, Lowry RP, O'Brien DP, Warshaw BL, et al.

Clin Transpl. 1993:253-8. No abstract available.

PMID:
7918158
42.

Race and sex differences in the identification of candidates for renal transplantation.

Soucie JM, Neylan JF, McClellan W.

Am J Kidney Dis. 1992 May;19(5):414-9.

PMID:
1585927
43.

Conclusions: the maintenance of allograft acceptance.

Rodey GE, Neylan JF 3rd.

Clin Lab Med. 1991 Sep;11(3):763-71. Review.

PMID:
1934973
44.

Diagnosis of pancreatic transplant dysfunction: value of gadopentetate dimeglumine-enhanced MR imaging.

Fernandez MP, Bernardino ME, Neylan JF, Olson RA.

AJR Am J Roentgenol. 1991 Jun;156(6):1171-6.

PMID:
2028861
45.

Atrial natriuretic factor does not improve the outcome of cadaveric renal transplantation.

Sands JM, Neylan JF, Olson RA, O'Brien DP, Whelchel JD, Mitch WE.

J Am Soc Nephrol. 1991 Mar;1(9):1081-6.

46.

The effect of race on access and outcome in transplantation.

Kasiske BL, Neylan JF 3rd, Riggio RR, Danovitch GM, Kahana L, Alexander SR, White MG.

N Engl J Med. 1991 Jan 31;324(5):302-7. No abstract available.

47.

Supplemental Report.

Neylan JF.

Cal State J Med. 1913 Feb;11(2):93. No abstract available.

48.

Report Covering Affairs of State Board of Medical Examiners and Supplementary Report.

Neylan JF, Seavey CL, Nellis FC.

Cal State J Med. 1913 Feb;11(2):92-3. No abstract available.

49.

REPORT ON CONDITION OF ACCOUNTS OF STATE BOARD OF HEALTH.

Neylan JF, Seavey CL, Humphrey WH.

Cal State J Med. 1913 Feb;11(2):92. No abstract available.

Supplemental Content

Loading ...
Support Center